newsfilter
← Latest News
GlobeNewswire·

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY,